Abstract

Since the first described case in December 2019, the coronavirus disease 2019 (COVID-19) has been one of the most significant challenges of our time. The clinical spectrum ranges from asymptomatic to critical forms with acute respiratory distress syndrome and death. The most endangered patients are the adults older than 60 years, the patients with comorbidities, especially immunodeficiencies. A targeted therapy and exact treatment protocols are lacking due to the not fully known pathogenesis. Passive immunotherapy with convalescent plasma transfusion represents a potentially effective therapy for some patients with impaired cellular and humoral immunity. This could be a long-term, ”chronic” therapy for COVID-19 for this group of patients, especially for bridging the period when the immune system cannot produce by itself the antibodies needed for viral clearance.

Biography

Dr. Dina Rnjak was born in Osijek, Croatia in 1989. She obtained her medical degree at Faculty of medicine, Josip Juraj Strossmayer University of Osijek. Her residency was at Special Hospital for Lung Diseases Zagreb and at The Clinic for Lung Diseases, University Hospital Zagreb. Dr. Rnjak is a member of the Croatian Thoracic Society, Croatian Resoiratory Society, European Respiratory Society, Croatian Medical Association.

X